Study Finds No Link Between MMR Vaccine and Autism Risk

A recent study involving over 2.5 million children has determined that receiving the measles, mumps, and rubella (MMR) vaccine before the age of two does not increase the risk of autism. Published in The Pediatric Infectious Disease Journal, the research suggests that the timing of this vaccination is not related to a child’s likelihood of being diagnosed with the developmental disorder.

Autism spectrum disorder affects communication, social interaction, and how individuals perceive the world around them, with an estimated 3.2 percent of U.S. children currently affected. The MMR vaccine is a standard immunization aimed at preventing three highly contagious viral infections.

Despite substantial research, some parents still harbor worries that the routine vaccine may be linked to autism, often leading to delays or refusals in vaccination. This concern largely originates from a 1998 study—based on only 12 cases—that was later retracted due to ethical issues. Numerous large-scale studies conducted subsequently have not found a connection between the vaccine and autism.

However, analyzing vaccine safety can be complex. Factors such as a family’s healthcare practices, parental concerns about a child’s development, and the child’s age at vaccination can affect both vaccination timing and autism diagnosis. If studies fail to account for varying developmental stages, their results might be distorted. The research, led by Todd L. Burstain from UW Medicine, aimed to tackle these challenges with a more refined study design.

The study employed an age-anchored landmark analysis approach. This involved grouping children by the age range when vaccination decisions are typically made and comparing vaccinated and unvaccinated children within those categories to minimize bias.

For this study, the researchers examined data from Cosmos, a comprehensive electronic health record database from hospitals and clinics nationwide. The sample included 2,560,035 children who had at least one routine check-up between 12 and 24 months of age, with a prevalence of childhood autism at 2.55 percent. The focus was on a specific diagnosis code for childhood autism, which is narrower and partly explains the lower prevalence compared to national estimates.

Children diagnosed with autism before 11 months were excluded to ensure vaccination preceded any diagnosis. Follow-ups continued until children reached eight years old or until December 2024, with 91.4 percent of the sample having received their first MMR dose by 24 months.

The researchers categorized children into specific age groups, such as 11.5 to 12.5 months and onward, comparing vaccinated children with those unvaccinated throughout the follow-up period. They controlled for numerous variables that could influence both vaccination and autism diagnosis, like maternal age, ethnicity, birth conditions, and neighborhood factors, avoiding adjustments for post-vaccination developments that might skew results.

Across all age groups considered, there was no linkage between receiving the first vaccine dose and autism risk. The primary analysis—focusing on vaccinations between 11.5 and 24 months—showed an adjusted hazard ratio of 0.97, indicating no difference in risk since this range includes 1.0. This figure suggests a slight 3 percent lower diagnosis rate among vaccinated children, which isn’t statistically significant.

In later age categories, such as 14.5 to 17.5 months and 17.5 to 24 months, vaccinated children showed marginally lower autism rates, but the authors believe these slight variations are likely due to residual bias rather than any protective effect from the vaccine.

The findings remained consistent even with the inclusion of additional birth-related factors and when excluding neighborhood data, showcasing robust results across various analyses. To validate their approach, the researchers also examined a negative control group, looking at pneumococcal vaccine boosters given around 12 to 15 months, which should have no correlation to autism. The similar findings support the credibility of their analysis regarding the MMR vaccine.

Of course, it’s worth noting some limitations in the research. Since it was based on observational data, not every variable in a child’s life could be accounted for. For instance, the dataset lacked information on family histories of autism, which could bias results if parents with an autistic child are more cautious about vaccinating subsequent children.

Also, vaccinated children tended to have longer follow-up periods in the healthcare system compared to unvaccinated peers, which may create more chances for autism diagnosis. Despite this prolonged observation time, the study found no connection between vaccination and autism risk.

Moreover, the need for linked birth-parent records meant that many eligible children were excluded from the study, which might limit the findings’ applicability to all children seeking medical care.

Future research could integrate external family history and socioeconomic information to provide greater clarity. Researchers may also explore whether these results apply to broader autism spectrum disorder definitions beyond the specific childhood autism diagnostic code used here.

Overall, the study titled “Association Between First MMR Vaccination Before Age 2 Years and Childhood Autism in a U.S. EHR Cohort of 2.5 Million Children,” contributes to an ongoing discussion about vaccine safety and autism links.